Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
1895 1869.5 1897 1913 1915.5 Last
2611300 2921700 4379700 4257500 3629700 Volume
-0.60% -1.35% +1.47% +0.84% +0.13% Change
Financials (JPY)
Sales 2020 1 271 B
EBIT 2020 256 B
Net income 2020 203 B
Finance 2020 423 B
Yield 2020 2,14%
Sales 2021 1 280 B
EBIT 2021 266 B
Net income 2021 211 B
Finance 2021 594 B
Yield 2021 2,27%
P/E ratio 2020 16,8x
P/E ratio 2021 16,7x
EV / Sales2020 2,47x
EV / Sales2021 2,32x
Capitalization 3 560 B
More Financials
Company
Astellas Pharma specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (31.2%), Asia... 
More about the company
Surperformance© ratings of Astellas Pharma Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTELLAS PHARMA INC.
02/20Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation fo..
AQ
02/19ASTELLAS PHARMA : and Seattle Genetics Receive FDA Breakthrough Therapy Designat..
PU
02/12ASTELLAS PHARMA : XTANDI Demonstrates Significant Improvement in Overall Surviva..
AQ
02/11SEATTLE GENETICS : and Astellas Announce Updated Results from Phase 1b/2 Trial o..
AQ
02/06ASTELLAS PHARMA : Announces Management Structure
AQ
02/03ASTELLAS PHARMA : Announces Completion of Acquisition of Own Shares, and Cancell..
PU
01/31ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Evre..
AQ
01/31Astellas Pharma keeps profit forecast as prostate cancer drug sales rise
RE
01/31ASTELLAS PHARMA : Will Renew Its Corporate Website's Innovation Section
PU
01/28ASTELLAS PHARMA INC. : quaterly earnings release
01/23ASTELLAS PHARMA : Amgen astellas biopharma to become a wholly owned amgen affili..
PU
01/17ASTELLAS PHARMA : Announces Construction of New Manufacturing Facility for Activ..
AQ
01/14Amgen CEO expects 25% of growth to come from Asia in next decade
RE
01/09ASTELLAS PHARMA INC. : - U.S. FDA Approves Supplemental New Drug Application for..
AQ
01/05ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
PU
More news
News in other languages on ASTELLAS PHARMA INC.
02/11PFIZER : amélioration significative pour un traitement
01/28ASTELLAS PHARMA INC. : publication des résultats trimestriels
01/28ASTELLAS PHARMA INC. : Veröffentlichung des Quartalsergebnisses
01/24Tokyo finit sur un petit rebond une séance en dents de scie
01/23Tokyo hésite dans les premiers échanges
More news
Analyst Recommendations on ASTELLAS PHARMA INC.
More recommendations
Sector news : Pharmaceuticals - NEC
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/21ALLERGAN : Form 8.3 -
DJ
02/21ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 2 120,83  JPY
Last Close Price 1 915,50  JPY
Spread / Highest target 46,2%
Spread / Average Target 10,7%
Spread / Lowest Target -21,7%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Senior Executive Officer & Head-Finance
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.-1.11%31 759
JOHNSON & JOHNSON2.10%390 914
ROCHE HOLDING AG10.08%298 571
NOVARTIS2.89%217 737
MERCK AND COMPANY-9.30%210 018
PFIZER-7.53%198 398